Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection

被引：0
|
作者：
A Dewdney
D Cunningham
Y Barbachano
I Chau
机构：
[1] Royal Marsden Hospital,Department of Medicine
来源：
British Journal of Cancer | 2012年 / 106卷
关键词：
hypertension; colorectal; metastatic; bevacizumab; biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1718 / 1721
页数：3
相关论文
共 13 条
  • [1] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    Dewdney, A.
    Cunningham, D.
    Barbachano, Y.
    Chau, I.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1718 - 1721
  • [2] A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
    Wong, R.
    Cunningham, D.
    Barbachano, Y.
    Saffery, C.
    Valle, J.
    Hickish, T.
    Mudan, S.
    Brown, G.
    Khan, A.
    Wotherspoon, A.
    Strimpakos, A. S.
    Thomas, J.
    Compton, S.
    Chua, Y. J.
    Chau, I.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2042 - 2048
  • [3] BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection
    Wong, R.
    Saffery, C.
    Barbachano, Y.
    Chau, I.
    Valle, J.
    Hickish, T.
    Mudan, S.
    Khan, A.
    Chua, Y. J.
    Cunningham, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 345
  • [4] A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808)
    Uetake, Hiroyuki
    Yasuno, Masamichi
    Ishiguro, Megumi
    Kameoka, Shingo
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Watanabe, Toshiaki
    Muro, Kei
    Baba, Hideo
    Yamamoto, Junji
    Mizunuma, Nobuyuki
    Tamagawa, Hiroshi
    Mochizuki, Izumi
    Kinugasa, Yusuke
    Matsubara, Yoshihiro
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)
    Hiroyuki Uetake
    Masamichi Yasuno
    Megumi Ishiguro
    Shingo Kameoka
    Yasuhiro Shimada
    Keiichi Takahashi
    Toshiaki Watanabe
    Kei Muro
    Hideo Baba
    Junji Yamamoto
    Nobuyuki Mizunuma
    Hiroshi Tamagawa
    Izumi Mochizuki
    Yusuke Kinugasa
    Takashi Kikuchi
    Kenichi Sugihara
    Annals of Surgical Oncology, 2015, 22 : 908 - 915
  • [6] A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)
    Uetake, Hiroyuki
    Yasuno, Masamichi
    Ishiguro, Megumi
    Kameoka, Shingo
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Watanabe, Toshiaki
    Muro, Kei
    Baba, Hideo
    Yamamoto, Junji
    Mizunuma, Nobuyuki
    Tamagawa, Hiroshi
    Mochizuki, Izumi
    Kinugasa, Yusuke
    Kikuchi, Takashi
    Sugihara, Kenichi
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (03) : 908 - 915
  • [7] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Nikol Snoeren
    Emile E Voest
    Andre M Bergman
    Otilia Dalesio
    Henk M Verheul
    Rob AEM Tollenaar
    Joost RM van der Sijp
    Sander B Schouten
    Inne HM Borel Rinkes
    R van Hillegersberg
    BMC Cancer, 10
  • [8] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Snoeren, Nikol
    Voest, Emile E.
    Bergman, Andre M.
    Dalesio, Otilia
    Verheul, Henk M.
    Tollenaar, Rob A. E. M.
    van der Sijp, Joost R. M.
    Schouten, Sander B.
    Rinkes, Inne H. M. Borel
    van Hillegersberg, R.
    BMC CANCER, 2010, 10
  • [9] A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer
    Voest, E. E.
    Snoeren, N.
    Schouten, S. B.
    Bergman, A. M.
    van Werkhoven, E.
    Loosveld, O. J. L.
    van Gulik, T. M.
    Smit, J. M.
    Cats, A.
    Boven, E.
    Hesselink, E.
    Rijken, A.
    Tol, M.
    Dalesio, O.
    Verheul, H. M.
    Tollenaar, R. A.
    van der Sijp, J.
    Rinkes, I. Borel
    van Hillegersberg, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival.
    Tamagawa, Hiroshi
    Uetake, Hiroyuki
    Ishiguro, Megumi
    Mizunuma, Nobuyuki
    Kinugasa, Yusuke
    Mochizuki, Izumi
    Hamaguchi, Tetsuya
    Hasegawa, Junichi
    Katsumata, Kenji
    Ishibashi, Keiichiro
    Ogata, Yutaka
    Takii, Yasumasa
    Ooshiro, Mitsuru
    Kagimura, Tatsuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12